SCHEMBL3323143

SCHEMBL3323143

O[C@@H]1[C@H](O)CS[C@H]1n1cnc2c(NCc3cccc(I)c3)ncnc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 18/20 1.00
▸ ADORA1 P30542 17/20 1.00
▸ ADORA3 P0DMS8 15/20 1.00
▸ PPARD Q03181 4/20 0.76
▸ PPARG P37231 1/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13298748 1.00 ADORA2A (1.00) ADORA2AADORA1ADORA3PPARDPPARG
SCHEMBL13318025 1.00 ADORA2A (1.00) ADORA2AADORA1ADORA3PPARDPPARG
SCHEMBL24414330 1.00 ADORA2A (1.00) ADORA2AADORA1ADORA3PPARDPPARG
SCHEMBL30513698 1.00 ADORA2A (1.00) ADORA2AADORA1ADORA3PPARDPPARG
SCHEMBL29700194 0.90 ADORA2A (1.00) ADORA2AADORA1ADORA3PPARDPPARG
SCHEMBL21704479 0.90 ADORA2A (1.00) ADORA2AADORA1ADORA3PPARDPPARG
SCHEMBL13317693 0.90 ADORA2A (1.00) ADORA2AADORA1ADORA3PPARDPPARG
SCHEMBL24414338 0.90 ADORA2A (1.00) ADORA2AADORA1ADORA3PPARDPPARG
SCHEMBL3328015 0.90 ADORA2A (1.00) ADORA2AADORA1ADORA3PPARDPPARG
SCHEMBL13298743 0.90 ADORA2A (1.00) ADORA2AADORA1ADORA3PPARDPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9018371-B2 Adenosine derivatives, method for the synthesis thereof, and the pharmaceutical compositions for the prevention and treatment of the inflammatory diseases containing the same as an active ingredient FM THERAPEUTICS CO., LTD. (KR) 2015-04-28 — — US claimed
EP-2142549-B1 ADENOSINE DERIVATIVES, METHOD FOR THE SYNTHESIS THEREOF, AND THE PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF THE INFLAMMATORY DISEASES CONTAINING THE SAME AS AN ACTIVE INGREDIENT FM THERAPEUTICS CO LTD (KR) 2013-07-10 — — EP claimed
US-20100137577-A1 ADENOSINE DERIVATIVES, METHOD FOR THE SYNTHESIS THEREOF, AND THE PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF THE INFLAMMATORY DISEASES CONTAINING THE SAME AS AN ACTIVE INGREDIENT FUTURE MEDICINE CO., LTD. (KR) 2010-06-03 — — US claimed
US-20240325399-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CHOLANGITIS OR LIVER DISEASE CAUSED BY CHOLANGITIS COMPRISING ADENOSINE DERIVATIVE FUTURE MEDICINE CO., LTD. (KR) 2024-10-03 — — US disclosed
US-12083140-B2 Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative FUTURE MEDICINE CO., LTD. (KR) 2024-09-10 — — US disclosed
EP-3603647-B1 PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING GLAUCOMA, CONTAINING ADENOSINE DERIVATIVE FUTURE MEDICINE CO LTD (KR) 2024-08-21 — — EP disclosed
EP-4234021-A2 PHARMACEUTICAL COMPOSITION COMPRISING AN ADENOSINE DERIVATIVE FOR USE IN THE PREVENTION OR TREATMENT OF DIABETIC NEPHROPATHY Future Medicine Co., Ltd. (KR) 2023-08-30 — — EP disclosed
EP-3650029-B1 PHARMACEUTICAL COMPOSITION COMPRISING AN ADENOSINE DERIVATIVE FOR USE IN THE PREVENTION OR TREATMENT OF DIABETIC NEPHROPATHY FUTURE MEDICINE CO LTD (KR) 2023-06-28 — — EP disclosed
EP-4186514-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CHOLANGITIS OR LIVER DISEASE CAUSED BY CHOLANGITIS COMPRISING ADENOSINE DERIVATIVE Future Medicine Co., Ltd. (KR) 2023-05-31 — — EP disclosed
WO-2023286963-A1 PHARMACEUTICAL COMPOSITION INCLUDING ADENOSINE DERIVATIVE FOR PREVENTING OR TREATING CHOLANGITIS OR CHOLANGITIS-INDUCED LIVER DISEASE 퓨쳐메디신 주식회사 2023-01-19 — — WO disclosed
US-20220143029-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING NONALCOHOLIC STEATOHEPATITIS, HEPATIC FIBROSIS, AND LIVER CIRRHOSIS, COMPRISING ADENOSINE DERIVATIVES FUTURE MEDICINE CO., LTD. (KR) 2022-05-12 — — US disclosed
EP-3650029-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING DIABETIC NEPHROPATHY INCLUDING ADENOSINE DERIVATIVE Future Medicine Co., Ltd. (KR) 2020-05-13 — — EP disclosed
CN-110869030-A Pharmaceutical composition for preventing and treating diabetic nephropathy comprising adenosine derivative 未来制药有限公司 2020-03-06 — — CN disclosed
US-20200046711-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING NONALCOHOLIC STEATOHEPATITIS, HEPATIC FIBROSIS, AND LIVER CIRRHOSIS, COMPRISING ADENOSINE DERIVATIVES FUTURE MEDICINE CO., LTD. (KR) 2020-02-13 — — US disclosed
EP-3603647-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING GLAUCOMA, CONTAINING ADENOSINE DERIVATIVE Future Medicine Co., Ltd. (KR) 2020-02-05 — — EP disclosed
EP-3533452-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING NONALCOHOLIC STEATOHEPATITIS, HEPATIC FIBROSIS, AND LIVER CIRRHOSIS, COMPRISING ADENOSINE DERIVATIVES Future Medicine Co., Ltd. (KR) 2019-09-04 — — EP disclosed
US-9018371-B2 Adenosine derivatives, method for the synthesis thereof, and the pharmaceutical compositions for the prevention and treatment of the inflammatory diseases containing the same as an active ingredient FM THERAPEUTICS CO., LTD. (KR) 2015-04-28 — — US disclosed
EP-2142549-B1 ADENOSINE DERIVATIVES, METHOD FOR THE SYNTHESIS THEREOF, AND THE PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF THE INFLAMMATORY DISEASES CONTAINING THE SAME AS AN ACTIVE INGREDIENT FM THERAPEUTICS CO LTD (KR) 2013-07-10 — — EP disclosed
WO-2012125400-A1 COMPOSITIONS AND METHODS USING ADENOSINE A3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY EYE DISEASES ACORN BIOMEDICAL, INC. (US) 2012-09-20 — — WO disclosed
US-20100137577-A1 ADENOSINE DERIVATIVES, METHOD FOR THE SYNTHESIS THEREOF, AND THE PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF THE INFLAMMATORY DISEASES CONTAINING THE SAME AS AN ACTIVE INGREDIENT FUTURE MEDICINE CO., LTD. (KR) 2010-06-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12083140-B2 Pharmaceutical composition for preventing and treating glaucoma, containing adenosine derivative ADORA1, ADORA2A, ADORA3 ADORA2A 2/4885ADORA1 1/4885ADORA3 3/4885
US-20240325399-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CHOLANGITIS OR LIVER DISEASE CAUSED BY CHOLANGITIS COMPRISING ADENOSINE DERIVATIVE SLC10A1, ABCB11, SLC10A2 ADORA2A 8/4885ADORA1 4/4885ADORA3 11/4885
US-20100137577-A1 ADENOSINE DERIVATIVES, METHOD FOR THE SYNTHESIS THEREOF, AND THE PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF THE INFLAMMATORY DISEASES CONTAINING THE SAME AS AN ACTIVE INGREDIENT ADORA3, ADORA2A, ADORA1 ADORA2A 2/4885ADORA1 3/4885ADORA3 1/4885
US-20220143029-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING NONALCOHOLIC STEATOHEPATITIS, HEPATIC FIBROSIS, AND LIVER CIRRHOSIS, COMPRISING ADENOSINE DERIVATIVES SLC10A1, LIPC, ADORA1 ADORA2A 5/4885ADORA1 3/4885ADORA3 6/4885
US-20200046711-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING NONALCOHOLIC STEATOHEPATITIS, HEPATIC FIBROSIS, AND LIVER CIRRHOSIS, COMPRISING ADENOSINE DERIVATIVES SLC10A1, ADORA1, LIPC ADORA2A 5/4885ADORA1 2/4885ADORA3 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback